Pharmaceutical

Jazz Pharma’s Enrylaze wins European approval for AML and LBL

The European Commission has approved Enrylaze for treating acute lymphoblastic leukaemia and lymphoblastic lymphoma.

Sep 23, 2023 - 20:00
Jazz Pharma’s Enrylaze wins European approval for AML and LBL
The European Commission has approved Enrylaze for treating acute lymphoblastic leukaemia and lymphoblastic lymphoma.
Read the original article

Tags:

Previous Article

FDA clears Krystal Biotech’s IND for Type 1 AATD treatment KB408

Next Article

Over half of world’s population not covered by essential healthcare services

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Drugmakers push back on a clever tactic employers use to avoid paying for specialty medicines

STAT+: Drugmakers push back on a clever tactic employer...

Mar 24, 2023

Aseptic lyophilisation: Opportunities to improve quality and process monitoring with mass spectrometry

Aseptic lyophilisation: Opportunities to improve qualit...

Mar 23, 2023

STAT+: White House touts incremental step in Medicare drug price negotiation: counteroffers

STAT+: White House touts incremental step in Medicare d...

Mar 4, 2024